These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN. AIDS; 2003 Jul 01; 17 Suppl 3():S49-54. PubMed ID: 14565609 [Abstract] [Full Text] [Related]
25. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM. AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217 [Abstract] [Full Text] [Related]
27. Efficient monitoring of HIV-1 vertically infected children in Kenya on first-line antiretroviral therapy. Lihana RW, Lwembe RM, Bi X, Ochieng W, Panikulam A, Palakudy T, Musoke R, Owens M, Ishizaki A, Okoth FA, Songok EM, Ichimura H. J Clin Virol; 2011 Oct 20; 52(2):123-8. PubMed ID: 21798798 [Abstract] [Full Text] [Related]
29. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH. Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741 [Abstract] [Full Text] [Related]
30. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M. AIDS; 2007 May 11; 21(8):939-46. PubMed ID: 17457087 [Abstract] [Full Text] [Related]
32. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V. Clin Infect Dis; 2005 Jul 01; 41(1):100-7. PubMed ID: 15937769 [Abstract] [Full Text] [Related]
35. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA. BMC Infect Dis; 2006 Jul 11; 6():107. PubMed ID: 16834769 [Abstract] [Full Text] [Related]
36. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. HIV Med; 2008 May 11; 9(5):317-21. PubMed ID: 18331562 [Abstract] [Full Text] [Related]
37. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group. Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319 [Abstract] [Full Text] [Related]
38. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin; 2009 Apr 01; 27(4):222-35. PubMed ID: 19246124 [Abstract] [Full Text] [Related]
39. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A, Spanish Group of Paediatric HIV Infection. Clin Infect Dis; 2006 Mar 15; 42(6):862-9. PubMed ID: 16477566 [Abstract] [Full Text] [Related]
40. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study. Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]